Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

Venlafaxine extended release (XR) in the treatment of panic disorder

Authors Kevin Kjernisted, Diane McIntosh

Published 15 March 2007 Volume 2007:3(1) Pages 59—69

Kevin Kjernisted, Diane McIntosh

University of British Columbia, Vancouver, British Columbia, Canada

Abstract: Panic disorder is a chronic, recurrent illness, with a lifetime prevalence of about 5%. It is associated with substantial functional impairment, and studies suggest that treatment with medication alone (and no instruction in exposure to feared and avoided situations) is less than optimal. In fact, 40%–90% of patients in long-term follow-up studies in the late 1980s and early 1990s, treated with antidepressants or high potency benzodiazepines alone, remained somewhat symptomatic. Venlafaxine extended release (XR) was effective and well tolerated in both the short-term and long-term treatment of panic disorder. In 12-week trials, venlafaxine XR was significantly more effective than placebo in achieving a panic-free state (54%–70% vs 34%–48%, p≤0.05), and was as effective as paroxetine. In addition, venlafaxine XR has been shown to produce significantly higher response and remission rates than placebo. Relapse rates were significantly reduced with ongoing venlafaxine XR treatment compared to switching to placebo (22% vs 50%, p≤0.001), in a 6 month study. Importantly, venlafaxine XR significantly improved patient quality of life and functioning, and was generally well tolerated.

Keywords: venlafaxine XR, panic disorder, anxiety disorders, quality of life

Download Article [PDF] 

Readers of this article also read:

Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort

Nietert PJ, Shaftman SR, Silver RM, Wolf BJ, Egan BM, Hunt KJ, Smith EA

Clinical Epidemiology 2015, 7:161-168

Published Date: 3 February 2015

The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Collection of baseline data from the first 580 patients

Thomsen RW, Nielsen JS, Ulrichsen SP, Pedersen L, Hansen AM, Nilsson T

Clinical Epidemiology 2012, 4:43-48

Published Date: 21 September 2012

Conservative treatment for late-onset bleb leaks after trabeculectomy with mitomycin C in patients with ocular surface disease

Sagara H, Iida T, Saito K, Noji H, Ogasawara M, Oyamada H

Clinical Ophthalmology 2012, 6:1273-1279

Published Date: 8 August 2012

Validity of a procedure to identify patients with chronic idiopathic thrombocytopenic purpura in the Danish National Registry of Patients

Katrine Edith Klith Heden, Annette Østergaard Jensen, Dora Körmendiné Farkas, Mette Nørgaard

Clinical Epidemiology 2009, 1:7-10

Published Date: 19 February 2009

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Therapeutics and Clinical Risk Management 2007, 3:13-17

Published Date: 15 March 2007

Drug management in chronic rhinosinusitis: identification of the needs

Jean-Baptiste HPJ Watelet, Philippe H Eloy, Paul B van Cauwenberge

Therapeutics and Clinical Risk Management 2007, 3:47-57

Published Date: 15 March 2007

Optimal timing for antihypertensive dosing: focus on valsartan

Ramón C Hermida, Diana E Ayala, Carlos Calvo

Therapeutics and Clinical Risk Management 2007, 3:119-131

Published Date: 15 March 2007

Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia

R Lozano, MG Peralta Concha, A Montealegre, L de Leon, J Ortiz Villalba, et al

Therapeutics and Clinical Risk Management 2007, 3:149-155

Published Date: 15 March 2007